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2014, accepted Jantherosclerosis, the main pathophysiological condition leading to cardiovascular disease (CVD), is now considered to
be a chronic inﬂammatory condition. Statins are the most widely used and promising agents in treating CVD and are
renowned for their pleiotropic lipid-lowering independent effects. Statins exert their anti-inﬂammatory effects on the
vascular wall through a variety of molecular pathways of the innate and adaptive immune systems, their impact
on the circulating levels of pro-inﬂammatory cytokines, and their effect on adhesion molecules. By inhibiting the
mevalonate pathway and isoprenoid formation, statins account for the increase of nitric oxide bioavailability and the
improvement of vascular and myocardial redox state by multiple different mechanisms (directly or indirectly through
low-density lipoprotein [LDL] lowering). A large number of randomized control trials have shown that statins help
in the primary and secondary prevention of cardiovascular events, not only via their lipid-lowering effect, but also
due to their anti-inﬂammatory potential as well. In this paper, we examine the molecular pathways in which statins
are implicated and exert their anti-inﬂammatory effects, and we focus speciﬁcally on their impact on innate and
adaptive immunity systems. Finally, we review the most important clinical data for the role of statins in primary and
secondary prevention of cardiovascular events. (J Am Coll Cardiol 2014;63:2491–502) ª 2014 by the American
College of Cardiology FoundationCardiovascular disease (CVD) is the leading cause of mor-
bidity and mortality worldwide, with atherosclerosis being
the main pathophysiological condition leading to CVD.
Atherosclerosis, once thought to be a lipid storage disease, is
now considered a chronic low-grade inﬂammatory condition
that affects the vascular wall. It is characterized by the
deposition of cholesterol and lipids followed by inﬁltration
of T cells and macrophages, all as a result of an endothe-
lial injury response (1) (Fig. 1). Oxidative stress is also a key
factor in the development of atherosclerosis. Reactive oxygen
species (ROS) are capable of not only damaging the cellular
components of the vascular wall but also affecting several
redox-sensitive transcriptional pathways, shifting the tran-
scriptomic proﬁle to a proatheromatic state. ROS are re-
sponsible for the oxidation of the endothelial nitric oxide
synthase (eNOS) cofactor tetrahydrobiopterin (BH4) to
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uary 29, 2014.eNOS, promoting eNOS uncoupling. This results in the
production of superoxide, further promoting endothelial
dysfunction (2). Furthermore, in the subendothelial space,
ROS oxidize low-density lipoprotein (LDL) to oxidized
low-density lipoprotein (ox-LDL). The LDL oxidation
hypothesis was ﬁrst proposed in 1984 (3), and it is presently
widely accepted as the hallmark event for the initiation of
atherosclerosis. Each LDL particle contains several particles,
such as triglycerides, free cholesterol, phospholipids, and
cholesteryl esters. LDL oxidation by ROS can occur at
several sites of inﬂammation as well as in the artery wall.
Lipids and most importantly polyunsaturated fatty acids can
undergo oxidation from ROS and yield several byproducts
such as aldehydes, which in turn react with lysine and tyro-
sine of apolipoprotein B-100, resulting in loss of function (4).
This leads to the formation of minimally modiﬁed LDL,
exerting proatherogenic effects as it is recognized by LDL
receptors but not from any ligands of scavenger receptors.
The ox-LDL activates endothelial cells to produce pro-
inﬂammatory molecules, promoting formation of foam cells
while inhibiting NO-induced vasodilation (5). Meanwhile,
oxidation of high-density lipoprotein diminishes its anti-
atherogenic properties, contributing to the development of
atherosclerosis. As the lesion matures, atherosclerotic plaques
gradually lead to narrowing of the lumen and occlusion of the
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2492vessel. Plaque ulceration or
rupture may also occur, leading to
acute thrombosis and occlusion
of the vascular lumen. This
manifests as acute myocardial
infarction (MI), stroke, or acute
ischemia of any organ perfused by
that arterial branch depending on
the site of occlusion (6).The com-
pletemechanism for the formation
of atherosclerosis has not been fully
elucidated yet, but the theory of
atherogenesis continues to evolve
as new evidence underlying its
pathophysiology is obtained.Role of Redox-Sensitive
Transcriptional Pathways:Nuclear Factor-kappa B and Activator Protein-1
Nuclear factor-kappa B. Nuclear factor-kappa B (NF-kB)
consists of a family of 7 transcriptional factors, all sharing a
Rel homology domain, and can homo- or heterodimerize.
These factors are present in almost all mammalian cell types
(7). NF-kB activation can occur as a cellular response to
several stimuli, namely, ROS, DNA damage, ultraviolet
radiation, ox-LDL, cytokines, and bacterial and viral anti-
gens. As a gene network expression regulator, NF-kB is
implicated in several physiological and pathophysiological
processes such as response to stress, cardiovascular growth,
cancer, innate/adaptive immunity, cell survival, and others.
Although all of its subunits are ubiquitously expressed,
several distinct responses can be obtained depending on the
cell type and induced stimuli with NF-kB activation, leading
to a transcription of over 400 genes. Because it is a redox-
sensitive transcription factor, the redox balance within the
cells is a critical element of NF-kB activation (8). While
inactive, it is bound to its inhibitor (I-kBa/b) within the
cytoplasm (Fig. 2).
Activation of NF-kB following response to pro-inﬂam-
matory cytokines, such as tumor necrosis factor (TNF)-a and
interleukin (IL)-1 and IL-18, has been identiﬁed as the key
component in atherosclerosis development and progression.
Such activation results in up-regulation of genes encoding
pro-inﬂammatory cytokines, chemokines, adhesion mole-
cules, inducible nitric oxide synthase (iNOS), growth factors,
and enzymes, thus switching to a proatherogenic proﬁle.
These act via 2 signaling pathways, resulting in activating an
IkB kinase complex containing IKKa and IKKb kinases and
NF-kB essential modiﬁer (NEMO), a scaffold protein that
plays a regulating role (9,10). IkBa/b phosphorylation at
NH2-terminal serine residues is then initiated. The phos-
phorylated product is then ubiquitinated and undergoes
degradation by proteasome 26S. This releases the dimers from
the cytoplasmic complex and enables their nuclear trans-
location. Once inside, they bind to speciﬁc genes, resulting inthe ensuing transcription. Macrophages, endothelial cells
(ECs), and smooth muscle cells (SMC) of human athero-
sclerotic lesions have been reported to exhibit activated
NF-kB function (11–13).
Activator protein-1. Activator protein-1 (AP-1) is a
transcription factor consisting of the Jun (c-Jun, Jun-B,
Jun-D) and Fos (c-Fos, Fos-B, Fra-1, Fra-2) families of
transcriptional factors, binding to the 12-O-tetradecanoyl-
phorbol-13-acetate or cAMP response elements (14). The
gene products of this pathway can mitigate or amplify
oxidative stress and inﬂammatory responses. Phosphoryla-
tion of c-Jun by the stress-induced family of c-jun NH2-
terminal kinases (JNK) has been identiﬁed as a critical
step for the increased transcriptional activity of AP-1 (15).
The JNK pathway regulates a variety of pro-inﬂammatory
genes encoding cytokines, adhesion molecules, and metal-
loproteinases (MMPs) (16).This regulation is achieved via
interaction of JNK with AP-1 pathways along with other
transcription factors (10).
In atherosclerotic plaques, ROS production by cells can
have a critical effect on both of the transcriptional pathways.
ROS may oxidize NF-kB subunits, rendering them inca-
pable of binding with DNA and subsequently impairing
their transcriptional activities. On the other hand, excess
ROS production can lead to increased activation of the JNK/
AP-1 pathway, thus creating a new interaction state between
these 2 pathways, which has a great impact on pro-inﬂam-
matory molecule production (17).
Pro-Inﬂammatory Cytokines and
Adhesion Molecules in Atherosclerosis
Cytokines are small, cell-signaling protein molecules that
may have autocrine or paracrine actions that mediate short-
range intracellular communication (Table 1). The cytokine
family consists of more than 100 factors subcategorized into
several smaller clusters, such as ILs, interferons (INFs),
colony-stimulating factors, TNFs, and chemokines (18).
Cellular sources of cytokines include vascular cells, leuko-
cytes, platelets, and mast cells (10). Pro-inﬂammatory cy-
tokines owe their proatherogenic potential to several
biological effects. At the very ﬁrst stages of atherosclerosis,
endothelial function can be greatly altered by cytokine
release. TNF-a causes increased cytosolic Ca2þ and activa-
tion of myosin light chain kinase, as well as Ras homolog
gene family member A (RhoA), causing disruption of
endothelial cell junctions, which facilitates leukocyte trans-
migration. TNF-a along with INF-g inhibit the formation
of F-actin stress ﬁbers by altering the cadherin-catenin
complex in the vascular endothelium (18).
In later stages of the disease, cytokines such as TNF-a,
INF-g, and IL-1 may induce macrophage and SMC
apoptosis, resulting in destabilization of the atheromatic
plaque, making it prone to rupturing. Plaque destabilization
is further promoted by matrix degradation, which is accel-
erated by pro-inﬂammatory cytokine release. The latter
Figure 1 Overview of Mechanisms Involved in Atherosclerosis
Low-density lipoprotein (LDL) is oxidized in the presence of reactive oxygen species (ROS) and binds to proteoglycans (heparin sulfate) while simultaneously stimulating the
endothelium, leading to adhesion molecule overexpression and increasing its permeability. Apart from this action, oxidized low-density lipoprotein (ox-LDL) inhibits nitric oxide
(NO) production, prohibiting vasodilation. Furthermore, cytokines and other chemoattractant molecules, such as MCP-1, are secreted, favoring leukocyte adhesion. Leukocytes
come into random contact with the activated endothelium and, due to interactions with adhesion molecules, roll and tether and are subsequently ﬁrmly arrested. In addition,
leukocytes transmigrate into the subendothelial space, where they differentiate into macrophages, which in turn take up ox-LDL, forming foam cells. Ox-LDL antigens are
presented by macrophage major histocompatibility complex class II (MHC-II) proteins and are recognized by CD4þ T cells. These preferentially differentiate into Th-1 cells, pro-
inﬂammatory cytokine production. Finally, smooth muscle cell (SMC) proliferation and migration are induced as a result of cytokine and growth factor secretion.
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2493action has a great impact on the expression of MMPs and
their inhibitors, tissue inhibitors of metalloproteinases
(TIMPs), which act synergistically along with other mole-
cules to exert the remodeling of the extracellular matrix (16).
Cytokines also contribute to cell apoptosis. Macrophage
apoptosis leads to the enlargement of the lipid core, while
plaque-present SMC apoptosis contributes to the thinning
of the ﬁbrous cap, rendering it rupture prone. In addition,
cytokines and, more speciﬁcally, TNF-a and IL-1 have a
direct prothrombotic potential while inhibiting endogenous
ﬁbrinolytic/antithrombotic mechanisms (13). This results in
precipitation of thrombus formation, promoting the devel-
opment of acute coronary syndromes (ACS) (18). Finally
cytokines not only attenuate NO synthesis, a physiological
regulator of vascular tone, but they also induce synthesis
of acute-phase proteins such as C-reactive protein (CRP),
serum amyloid A, plasminogen, and ﬁbrinogen, which in
turn, ampliﬁes inﬂammatory responses (13).
Cytokines are also responsible for up-regulation of
adhesion molecules on the vascular endothelium, which in
turn, mediate leukocyte adhesion, greatly facilitating their
rolling and subendothelial migration (13). INF-g can greatlyaccelerate transformation of macrophages to foam cells as
it up-regulates the scavenger receptor of ox-LDL and the
phosphatidyl serine SR-PSOX. In each stage of this process,
several distinct adhesion molecules are involved. There are
P-, E-, and L-selectins and immunoglobulin-like molecules
(intracellular cell adhesion molecule [ICAM]), ICAM-1,
ICAM-2, and ICAM-3; vascular cell adhesion molecule
(VCAM)-1; and platelet endothelial cell adhesion
molecule-1 (PECAM-1). Following endothelial activation
from cytokine release, P-selectin glycoprotein ligand-1
(PSGL-1), CD34, and E-selectin ligand-1 (ESL-1) favor
the recruitment and binding of leukocytes after random
contact with the activated endothelium. Subsequently E-,
P-, and L-selectins promote rolling and tethering of leu-
kocytes whereas ICAM-1 and VCAM-1 mediate their
ﬁrm arrest. Finally, PECAM-1 facilitates leukocyte trans-
migration into the subendothelial space (13).
Innate and Adaptive Immunity in Atherosclerosis
From the start of the 19th century, researchers proposed that
there might be a link between atherogenesis and the immune
Figure 2 Overview of the NF-kB Redox-Sensitive Transcriptional Pathway in Endothelial Cells
Pro-inﬂammatory cytokines such as tumor necrosis factor (TNF)-a, interleukin (IL)-1b, and others induce activation of the canonical nuclear factor-kappa B (NF-kB) pathway with
the activation of Ikkb. TNF-a also down-regulates eNOS expression, resulting in reduced NO bioavailability. Tetrahydrobiopterin (BH4) undergoes oxidation to dihydrobiopterin
(BH2), resulting in endothelial nitric oxide synthase (eNOS) uncoupling and superoxide production. Other cytokines such as B-cell activating factor (BAFF), lipopolysaccharides
(LPS), and CD40 ligand (CD40L) induce activation of the noncanonical NF-kB pathway via activation of NF-kB-inducing kinase (NIK).
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2494system (19). As our knowledge about the mechanisms and
the processes involved in atherosclerosis evolves, it is now
well documented that the immune system is a key mediator
in the initiation and progression of atherosclerosis. First,
immune cells are present in atherosclerotic lesions, resulting
in speciﬁc pro-inﬂammatory gene expression. In addition,
endothelial dysfunction results, not only in loss of antith-
rombotic ability, but also in an imbalance of the immune
system, with the proatheromatic proﬁle prevailing over the
antiatheromatic state (20). Furthermore, most of the afore-
mentioned pro-inﬂammatory cytokines (ILs, TNFs, INFs)
along with several anti-inﬂammatory ones are all secreted
from immune cells throughout the atherosclerotic plaques.
Innate immunity. Innate, or nonspeciﬁc, immunity is the
host’s ﬁrst line of defense against pathogens, in a generic
way, lasting brieﬂy compared with the long-lasting action
of adaptive immunity. It is composed of endothelial or
epithelial barriers and circulating cells. Several receptors
responsible for both signaling and pattern recognition
participate in the innate immune system. A very interesting
category is the Toll-like receptors (TLRs). They are a
family of structurally conserved proteins able to recognize
pathogen-associated molecular patterns on viral and bac-
terial components and products (21). Binding of TLRs totheir ligands results in the recruitment and activation of
adapter proteins to propagate the signal, which in turn
activates the NF-kB and interferon pathways (21).
Dendritic cells (DCs) are considered messengers be-
tween the innate and adaptive immune systems. They act as
antigen-presenting cells, processing antigen material and
presenting it on their surface for other cells to recognize it.
In early atherosclerosis, disturbance in normal endothelial
function enhances DC migration and adhesion, resulting in
activated DCs (22). These may create clusters with T cells
inside atherosclerotic lesions, or they may migrate to
lymphoid organs and in turn induce T-cell activation,
triggering cytokine release.
Adaptive immunity. The adaptive or speciﬁc immune
system is a highly specialized defense mechanism responsible
for countering pathogens. Adaptive immunity participates
in the development of atherosclerosis in multiple ways: 1)
via interactions between antigen-presenting cells (macro-
phages, DCs, B cells) and naive T cells, which creates a
T-cell response; 2) T-cell cytokine release; and 3) antibody
secretion.
Most T cells involved in the atherogenic process dem-
onstrate a Th1 proﬁle, followed by production of high
amounts of INF-g, resulting in MMP overexpression,
Table 1
Summary of the Most Important Cytokines, Proteins,
and Enzymes Involved in the Atherosclerotic Process
Cytokine Role
IL-6 Pro-inﬂammatory cytokine activates several
adhesion molecules
IL-1b Pyrogenic cytokine is produced mostly by
monocytes
IL-10 Exhibits signiﬁcant anti-inﬂammatory effects and
acts via a feedback loop as a response to
excessive inﬂammatory effects; inhibits
macrophage activation via NF-kB pathway
IL-18 Signiﬁcant inﬂammatory effects; key role in
orchestrating the host defense systems against
various infections
Proteins and Enzymes
High-sensitivity CRP Pivotal role in innate immunity; very reliable
biomarker for general inﬂammation
Serum amyloid A Synthesized in the liver as a response to TNF, IL-1,
and IL-6 cytokine stimulation; elevated levels are
associated with low-grade inﬂammation
Lipoprotein-
associated
phospholipase A2
Unique roles in cleaving oxidized phospholipids and
creating pro-inﬂammatory and proapoptotic lipid
products
Fibrinogen Regulator of blood viscosity and ﬂow; ligand of
ICAM-1
CRP ¼ C-reactive protein; ICAM ¼ intracellular cell adhesion molecule; IL ¼ interleukin;
TNF¼ tumor necrosis factor.
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2495reduced collagen production, and thinning of the ﬁbrous
cap (23). In addition, INF-g activates antigen-presenting
cells, creating an ever-continuing circle of Th1 responses.
Also, IL-12 produced by DCs activates STAT4 and T-box
transcription factors expressed in T cells, leading to over-
expression of INF-g and attenuation of IL-4 and IL-5.
Interactions between CD40, expressed by cells of the im-
mune system and mostly in B cells, with its ligand CD40L,
promote Th1 responses, and it has been proposed that
inhibition of this pathway reduces atherosclerotic lesion
development and causes a shift to a more plaque-stable
proﬁle (24,25). Furthermore, ox-LDL, responsible for foam
cell formation, is also recognized as an antigen by the immune
system. Anti–ox-LDL antibodies have been detected in
patients with peripheral artery disease and CAD (26),
whereas increased levels of these antibodies may be used to
predict the severity of the disease. Human and microbial heat
shock protein (HSP) cross-reaction via molecular mimicry
may induce TLR-4 production in macrophages, further
linking innate and adaptive immunity with the atherosclerotic
process (27). Th2 cells are able to secrete several ILs (i.e., IL-
4, -5, and -10) and stimulate B cells. Although Th2 cells are
scarcely detected in atherosclerotic lesions, their production
is stimulated in hyperlipidemic conditions. Up-regulation
of IL-4 and IL-5 from differentiated Th2 cells suppresses
INF-g production, and it has been proposed that Th2
responses counter the proatherogenic potential of Th1-
mediated responses (23). However there is still a debate
about the exact role of Th2 cells in atherogenesis.
T regulatory cells (Tregs) can recognize speciﬁc self-
antigens, which thus helps to prevent autoimmuneresponses by destroying pathogenic lymphocytes. Tregs are
developed in the thymus and are maintained though simul-
taneous stimulation of the CD28-CD80/CD86 pathway.
Tregs express CD4, CD25, and Foxp3. Furthermore,
transforming growth factor (TGF)-b is a critical mediator of
immune system homeostasis because it inhibits T-cell
differentiation to Th1 and Th2 phenotypes and helps
maintain Treg function.
Targeting Inﬂammation for the
Treatment of Atherosclerosis
The most widely used and promising agents in cardiovas-
cular disease, hydroxymethylglutaryl-coenzyme A (HMG-
CoA) reductase inhibitors, or statins, are renowned for
their “pleiotropic” lipid-lowering independent effects. Even
though this concept has recently been challenged, data from
large meta-analyses conﬁrm that the beneﬁcial effects exer-
ted by statins in vascular disease states are independent
of their lipid-lowering properties (Table 2). Statin’s inhibi-
tion of the mevalonate pathway and its isoprenoid formation
have been proposed to account for many of these non–
lipid-lowering effects, because protein isoprenylation is
implicated in intracellular signaling events (28). Asymmet-
rical dimethyl arginine (ADMA) is believed to be an
important mediator of inﬂammation-induced endothelial
dysfunction, leading to atherogenesis. Statins suppress the
expression of pro-inﬂammatory mediators, resulting in
reduced circulating ADMA levels (29).
It is well established that agents such as angiotensin-
converting enzyme inhibitors (ACEI) and Ang-II receptor
blockers are more than simple blood pressure-lowering
drugs. Data suggest that these antihypertensive agents are
able to modulate vascular redox state because they actively
block angiotensin effects on the vascular wall. It is well
known that Ang-II exerts pro-oxidant, pro-inﬂammatory,
and proliferative effects on the vasculature mainly via the
constitutively expressed AT1R, whereas AT2R is consid-
ered to have anti-inﬂammatory properties. The sulfhydryl
ACEI zofenopril seems to have unique properties compared
with other ACEIs; zofenopril reduces oxidative stress and
enhances NO bioavailability in vitro in cell studies and
in vivo in hypertensive patients (30). In addition, losartan
inhibits Ang-II–induced expression of vascular remodeling
agents (31) and differentiation of adventitial ﬁbroblasts to
myoﬁbroblasts (32).
Statins and Their Anti-Inﬂammatory Effects:
General Role of Statins in Inﬂammation
HMG-CoA is the precursor for cholesterol synthesis.
HMG-CoA is formed by condensation of acetyl-CoA
and acetoacetyl-CoA, catalyzed by HMG-CoA synthase.
HMG-CoA reductase catalyzes the production of meval-
onate from HMG-CoA, in which the HMG-CoA
reductase reaction is the rate-limiting step for cholesterol
Table 2
Overview of Diverse Statin Action Through
Several Different Targets
Target Mechanism of Action
Inﬂammation  Inhibition of mevalonate synthesis
pathway
 Lowering of thrombus formation and
LDL levels
 Reduction of circulating ADMA levels
Redox-sensitive transcriptional
pathways
 Inhibition of vascular Rac1-mediated
activation of NADPH-oxidase
 Improvement of NO bioavailability
 Attenuation of vascular superoxide
reduction
 Endothelin-1 down-regulation
 COX-2 and prostacyclin up-regulation
 NF-kB, AP-1, and HIF-1 pathway
down-regulation
Innate immunity system  Reduction of MCP-1
 Up-regulation of ERK5
Adaptive immunity  Differentiation toward Tregs and
not Th-17
 Attenuation of Smad6 and Smad7;
inhibition of TGF-b signaling
 Blocking of CD4 T-cell–mediated
endothelial cell apoptosis
 Reduced T-cell expression of CD69
and TRAIL
Cytokines  Attenuation of IL-6, IL-8, and MCP-1
production
 Reduction of expression of several MMPs
Adhesion molecules  Inhibition of Rho post-transcriptional
modiﬁcations, thus attenuating the
expression of ICAM, PECAM, and VCAM
ADMA ¼ asymmetrical dimethyl arginine, AP ¼ activator protein; COX-2 ¼ cyclooxygenase-2;
ERK ¼ extracellular signal-regulated kinase; HIF ¼ hypoxia-inducible factor; ICAM ¼ intracellular
cell adhesion molecule; IL ¼ interleukin; LDL ¼ low-density lipoprotein; MCP ¼ monocyte che-
moattractant protein; MMP ¼ matrix metalloproteinase; NADPH ¼ nicotinamide adenine dinucle-
otide; NO ¼ nitric oxide; PECAM ¼ platelet endothelial cell adhesion molecule; Tregs ¼ regulatory T
cells; VCAM ¼ vascular cell adhesion molecule.
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2496synthesis. Mevalonate is phosphorylated by 2 phosphate
transfers from ATP, yielding the pyrophosphate deriva-
tive. Pyrophosphomevalonate decarboxylase catalyzes ATP-
dependent decarboxylation, with dehydration, to yield
isopentenyl pyrophosphate (isoprenylation). Isopentenyl
pyrophosphate is the ﬁrst compound in the mevalonate
pathway. The pleiotropic effects of statins are mediated by
inhibition of protein isoprenylation, altering several signal
transduction molecules in the cardiovascular pathways.
By inhibiting mevalonate synthesis, statins also prevent
the synthesis of other important isoprenoid intermediates
of the cholesterol biosynthetic pathway, such as farne-
sylpyrophosphate (FPP) and geranylgeranyl pyrophosphate
(GGPP) (33). These isoprenoid intermediates serve as
important lipid attachments for a variety of proteins,
including the small guanosine triphosphate (GTP) binding
proteins Ras, Rho, and Rac. Rho proteins are involved in
the expression of pro-inﬂammatory cytokines; Rac pro-
teins modulate ROS generation, whereas Ras proteins are
involved in cell proliferation, apoptosis, and cell adhesion (28).
Inhibition of Ras and Rho isoprenylation by statins renders
them inactive. It has been demonstrated that co-incubationof human vessels with statins and mevalonate reverses the
beneﬁcial effects of statins on vascular redox state (34,35);
such ﬁndings highlight the importance of the mevalonate
pathway in mediating the pleiotropic effects of statins
in humans. Statins lower LDL cholesterol by inhibiting
HMG-CoA reductase. The lipid-lowering effect of statins
on the reduction of cardiovascular events has been well
established over the years through large randomized trials
(36,37). Furthermore, statin treatment exhibited a reduction
in thrombus formation along with lowering of LDL levels in
hyperlipidemic patients (38).
Effect of Statins on Primary and
Secondary Prevention of Cardiovascular Events
As discussed previously, statins are widely used for their lipid-
lowering effects because their beneﬁts have been well estab-
lished through large clinical trials. However, the emerging
role of statins in primary and secondary prevention of coro-
nary events is the issue for discussion. Numerous large ran-
domized clinical trials have demonstrated a variety of the
non–lipid-lowering effects of statins (39–45). A brief sum-
mary of the most important randomized clinical trials is given
in Table 3. In theMRC/BHFHeart Protection Study of more
than 20,000 participants with coronary heart disease (CHD),
occlusive arterial disease, or diabetes, simvastatin reduced all-
cause and coronary mortality as well as vascular events. Par-
ticipants were randomly allocated to receive either 40 mg of
simvastatin or matching placebo. All-cause mortality was
signiﬁcantly reduced in the simvastatin group due to a
highly signiﬁcant proportional reduction in the coronary
death rate. There were highly signiﬁcant reductions of
approximately one-quarter in the ﬁrst-event rate for
nonfatal MI or coronary death. For the ﬁrst occurrence of
any of these major vascular events, there was a deﬁnite
reduction in the event rate. During the ﬁrst year, there was
no signiﬁcant reduction in major vascular events, but subse-
quently, it was highly signiﬁcant during each separate year.
The proportional reduction in the event rate was similar (and
signiﬁcant) even in those who presented with LDL choles-
terol concentrations below 3.0 mmol/l (116 mg/dl) or total
cholesterol below 5.0 mmol/l (193 mg/dl) (42).
In addition, it was demonstrated in the TNT (Treating
to New Targets) trial with a total of 10,001 participants
with CHD, high doses of atorvastatin reduced the total
risk for major adverse cardiovascular events (MACE)
among these patients. The patients were randomly
assigned to receive either 10 mg or 80 mg of atorvastatin
and were followed for a median of 4.9 years. There was an
absolute reduction in MACE for the group of patients who
received a higher dose of atorvastatin (43), reﬂecting, not
only the beneﬁts of atorvastatin treatment, but also that of
the dosage as well.
It is now well established that statins exert a crucial role
in the primary prevention of acute coronary events. Results
from the AFCAPS/TexCAPS (Air Force/Texas Coronary
Table 3 Summary of Key Clinical Trials Examining the Role of Statins in Primary and Secondary Prevention of Cardiovascular Events
Primary Prevention
Study (Ref. #) Population Intervention Outcome
JUPITER (39) 17,802 subjects
(LDL<130mg/dl, CRP>2.0 mg/l
Rosuvastatin vs. placebo Rosuvastatin reduced risk for MACE (HR: 0.56; 95% CI: 0.46–0.69)
WOSCOPS (45) 6,595 men without CHD Pravastatin vs. placebo Pravastatin reduced coronary event(s) by 31% (95% CI: 17%–43%),
and coronary mortality by 32% (95% CI: 3%–53%)
SPARCL (85) 4,731 patients with stroke or
TIA, without known CHD
Atorvastatin 80 mg/day
vs. placebo
Reduced stroke risk (HR: 0.84; 95% CI: 0.71–0.99)
Reduced MACE risk (HR: 0.80; 95% CI: 0.69–0.92)
AFCAPS/Tex-CAPS (44) 6,605 subjects without CHD Lovastatin vs. placebo Lovastatin reduced incidence of ﬁrst acute major coronary event(s)
(RR: 0.63; 95% CI: 0.50–0.79)
Secondary Prevention
Stable Coronary Heart Disease
HPS (42) 20,536 CHD patients with,
occlusive arterial disease,
or diabetes
Simvastatin vs. placebo Simvastatin reduced all-cause and coronary mortality, and vascular
event(s) by 24% (95% CI: 19%–28%)
TNT (43) 10,001 CHD patients Atorvastatin (high vs. low dose) Reduced risk for MACEs with high dose treatment (HR: 0.78;
95% CI: 0.69–0.89)
4S (40) 4,444 CHD patients Simvastatin vs. placebo Simvastatin reduced risk of death (RR: 0.70; 95% CI: 0.58–0.85)
and coronary death (RR: 0.58; 95% CI: 0.46–0.73)
CARE (86) 4,159 patients with MI Pravastatin 40 mg/day vs.
placebo
Reduced risk for coronary or nonfatal MI by 24% (95% CI: 9%–36%)
LIPS (87) 1,677 patients with stable or
unstable angina or silent
ischemia after PCI
Fluvastatin 80 mg/day vs.
placebo
Reduced risk for MACE (RR: 0.78; 95% CI: 0.64–0.95)
LIPID (41) 9,014 CHD patients Pravastatin vs. placebo Pravastatin reduced coronary mortality risk by 24% (95% CI: 12%–35%)
Patients With or at High Risk For Developing Coronary Heart Disease
ASCOT-LLA (88) 10,305 hypertensive patients,
with at least 3 other risk
factors for CHD
Atorvastatin 10mg/day vs.
placebo
Reduced risk for primary event(s) (HR: 0.64; 95% CI: 0.50–0.83)
ALLHAT-LLT (89) 10,355 hypercholesterolemic,
hypertensive patients (>55 yrs)
with at least 1 additional CHD
risk factor
Pravastatin 40 mg/day vs.
usual care
No effect on all-cause mortality nor CHD
Patients With Acute Coronary Syndrome
A to Z trial (90) 4,497 ACS patients Simvastatin 40 mg/day for
1 month and then 80 mg/day
vs. placebo for 4 month and
then simvastatin 20 mg/day
Intensive simvastatin treatment demonstrated a favorable
trend toward reduction of MACE
PROVE IT–TIMI 22 (91) 4,162 ACS patients Atorvastatin 80 mg/day vs.
pravastatin 40 mg/day
Atorvastatin signiﬁcantly reduced primary endpoint by 16%
(95% CI: 5%–26%).
Patients With Heart Failure
CORONA (92) 5,011 ischemic, systolic
HF patients (age 60 yrs,
NYHA classes II–IV)
Rosuvastatin 10 mg/day vs.
placebo
No difference in coronary event(s) or death.
ACS ¼ acute coronary syndrome(s); ACOTT-LLA ¼ Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm; AFCAPS/TexCAPS ¼ Air Force/Texas Coronary Atherosclerosis Prevention Study;
ALLHAT-LLT ¼ Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; A-to-Z ¼ Aggrastat to Zocor; CABG ¼ coronary artery bypass graft; CARE ¼ Cholesterol and Recurrent Events;
CHD ¼ coronary heart disease; CI ¼ conﬁdence interval; CORONA ¼ Controlled Rosuvastatin Multinational Study in Heart Failure; CRP ¼ C-reactive protein; HF ¼ heart failure; HPS ¼ Heart Protection
Study; HR ¼ hazard ratio; JUPITER ¼ Justiﬁcation for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; LDL ¼ low-density lipoprotein; LIPID ¼ Long-Term Intervention with
Pravastatin in Ischaemic Disease; LIPS ¼ Lescol Intervention Prevention Study; MACE ¼major adverse cardiac event(s); MI ¼myocardial infarction; NYHA ¼ New York Heart Association; PCI ¼ percutaneous
coronary intervention; PROVE IT–TIMI ¼ Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction; RR ¼ relative risk; SPACL ¼ Stroke Prevention by
Aggressive Reduction in Cholesterol Levels; TIA ¼ transient ischemic attack; TNT ¼ Treating to New Targets; WOSCOPS ¼ West of Scotland Coronary Prevention Study; 4S ¼ Scandinavian Simvastatin
Survival Study.
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2497Atherosclerosis Prevention Study) (44) demonstrated just
that with participants who had no clinical evidence of
atherosclerotic cardiovascular disease. The subjects were
randomized to receive either lovastatin or placebo and
were followed for a median of 5.2 years. Treatment with
lovastatin reduced the incidence of MI, unstable angina,
coronary revascularization procedures, and cardiovascular
events. Furthermore, in the WOSCOPS (West ofScotland Coronary Prevention Study), pravastatin reduced
the coronary events and coronary mortality among 6,595
men with no history of MI, who received either 40 mg of
atorvastatin or placebo (45).
The JUPITER trial (39) was the ﬁrst trial that tried to
address the question of whether statins’ anti-inﬂammatory
effects could alter the clinical outcome in apparently
healthy men and women with low LDL levels. A total of
Tousoulis et al. JACC Vol. 63, No. 23, 2014
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249817,802 participants who had no history of CVD and an
LDL cholesterol level <130 mg/dl (3.4 mmol/l) and a
high-sensitivity CRP level of 2.0 mg/l or more during
the ﬁrst visit were eligible for the trial. The patients were
randomized in a 1:1 ratio to receive either 20 mg of
rosuvastatin or placebo. Rosuvastatin reduced LDL
cholesterol levels by 50% and high-sensitivity CRP levels
by 37% (hazard ratio [HR] for rosuvastatin, 0.56; 95%
conﬁdence interval [CI]: 0.46 to 0.69; p < 0.00001) for
the combined primary endpoint. The study demonstra-
ted that rosuvastatin reduced the incidence of major car-
diovascular events in apparently healthy, normolipidemic
subjects with elevated CRP levels (39). The study high-
lighted the fact that even in low- or intermediate-risk
patients without hypercholesterolemia, as established by
their Framingham risk score, statin-induced attenuation
of inﬂammation prevented CVD development and improved
clinical outcome (39). Although in clinical trials, it can be
only speculated that statin treatment can exert clinical beneﬁts
through the suppression of background inﬂammation, JU-
PITER’s data are in accordance with data from mechanistic
studies demonstrating the LDL-independent beneﬁcial
effects of statins. Therefore, the results from JUPITER
come to facilitate data interpretation from basic science
experiments into a clinical setting and cannot directly
support the pleiotropic effects of statins as a stand-alone
dataset. Other studies such as PRINCE (Pravastatin
Inﬂammation/CRP Evaluation) demonstrated that oral
administration of 40 mg/day pravastatin for a period of 24
weeks resulted in a signiﬁcant reduction of serum CRP
levels in subjects with and without CVD. These effects
were independent of any changes in LDL levels (46).
PRINCE conﬁrmed the anti-inﬂammatory effects of sta-
tins in primary and secondary prevention, although it was
not designed to access clinical outcome. In addition, other
smaller studies have veriﬁed the anti-inﬂammatory prop-
erties of statins through reduction in CRP and pro-in-
ﬂammatory cytokines levels in patients with metabolic
syndrome, diabetes mellitus, and hypercholesterolemia
(47–49). However, at a clinical level, it is still hard to
dissect the contribution of LDL-independent mechanisms
to the statin-induced reduction of cardiovascular risk.
Impact of Statins on Redox-Sensitive
Transcriptional Pathways
Inhibition of the mevalonate pathway and isoprenoid
formation by statins has been proposed to account for
many of these non–lipid-lowering effects because protein
isoprenylation is implicated in intracellular signaling
events (28). Experimental data have demonstrated that
statins have a favorable effect on vascular redox state by
both reducing ROS production and enhancing antioxidant
defense mechanisms. A major effect on vascular redox
state is the blunting of Ang-II effects on the vascular wall
by down-regulating AT1R expression and the reductionof NADPH oxidase (NOX)-derived ROS when stimu-
lated by Ang-II. This might involve inhibition of Rac1
isoprenylation and membrane translocation, which is re-
sponsible for NOX activation (50). Heme oxygenase-1, an
overall vasoprotective molecule, is up-regulated in human
umbilical vein and aortic endothelial cells with atorvastatin
treatment in vitro. Gene expression and activity of cellular
antioxidant enzymes such as catalase, SOD, and Trx-1
have also been shown to be up-regulated by statins (50–
52). In addition, statins improve endothelial function in
many ways. NO bioavailability is increased, not only by
statin-induced reduction in ROS production, but also by
direct effects on eNOS enzyme. We have recently shown
that short-term treatment with 40 mg of atorvastatin
per day before coronary artery bypass graft improves
redox state in saphenous vein grafts by inhibiting vascular
Rac1-mediated activation of NOX independently of LDL
levels (35). These antioxidant effects of atorvastatin were
reversed by mevalonate and support the notion that
even in patients with relatively low LDL, statins have
direct beneﬁcial antioxidant effects on blood vessels. We
also demonstrated that statins exert a direct effect on the
vascular wall through a BH4-mediated eNOS coupling, by
improving NO bioavailability and vascular superoxide re-
duction (34). Statin-induced activation of PI3 kinase-Akt
protein kinase pathway also increases NO production and
inhibits endothelial cell apoptosis. In addition, by sup-
pressing the expression of pro-inﬂammatory mediators,
statins reduce circulating ADMA plasma levels and
improve NO bioavailability (29). Furthermore, Rho kinase
inhibition by statins reduces pre-proendothelin-1 mRNA
expression and endothelin (ET)-1 bioavailability (28).
On the other hand, cyclooxygenase (COX)-2 and pros-
tacyclin, 2 key mediators of vascular redox, are also up-
regulated by statin treatment (53). These combined effects
favor endothelium-dependent vasodilation. Additionally,
simvastatin-induced vascular endothelial growth factor
(VEGF) production helps endothelial healing in injured
hamster arteries (54). More importantly, studies have
shown that all the well-known redox-sensitive pro-
inﬂammatory transcription pathways, such as NF-kB,
AP-1, and HIF-1, are down-regulated by statin treat-
ment in VSMC (55), thus reducing proliferative and
migrative responses (56). In summary, experimental data
are in agreement with the positive ﬁndings of large
clinical trials regarding statins in vascular disease states.
Effect of Statins on Innate Immune Responses
Endothelial injury triggers innate immune responses
through leukocyte adhesion, transmigration, and movement
of proteins out of the capillaries. Several studies have shown
that statins confer favorable properties on ECs through the
induction of the myeloid transcription factor KLF2 and its
target genes. A more recent study implicated KLF4, another
member of the Kruppel-like family, in mediating the anti-
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2499inﬂammatory effects of statins on ECs (57). The authors
demonstrated that statins up-regulate extracellular signal-
regulated kinase (ERK5) through the MEK5/mitogen-
activated protein kinase pathway. Endothelial oxidative
stress can induce an inﬂammatory phenotype and senes-
cence. We recently demonstrated that atorvastatin treatment
for 3 days improves vascular redox state in saphenous
vein grafts of patients undergoing coronary artery bypass
graft surgery by inhibiting Rac-1–mediated activation of
NADPH oxidase independently of LDL levels (35). IL-6 is
key mediator of innate immunity affecting the JAK/STAT3
signaling pathway. A recent study showed that statins pre-
vented the induction of monocyte chemoattractant protein
(MCP)-1 and monocyte chemotaxis by suppressing IL-6
on human aortic endothelial cells (58).
Effects of Statins on Adaptive Immunity System
Tregs are a component of the immune system that sup-
presses immune responses of other cells. Tregs come in
many forms, with the most well-understood being those that
express CD4, CD25, and Foxp3. CD4þFoxp3þ Tregs play
an essential role in regulating T-cell responses to both self
and foreign antigens. It has been suggested that statins may
promote the differentiation of Treg cells in the periphery
while blocking the differentiation of pro-inﬂammatory
helper T (Th17) cells (59). Statins divert T-cell differenti-
ation toward Tregs and away from Th17 cells via a mech-
anism dependent on protein geranylgeranylation. Foxp3þ T
cells develop in the thymus but can also be induced in pe-
ripheral sites in the presence of TGF-b. Kim et al. (60)
demonstrated that simvastatin blockade of the mevalonate
pathway can mediate induction of mouse Foxp3þ T cells
and that simvastatin can synergize with low levels of TGF-
b to induce Foxp3þ T cells. The effects of simvastatin were
secondary to a blockade of protein geranylgeranylation,
were mediated at late time points after T-cell activation,
and were associated with demethylation of the Foxp3
promoter. As demonstrated, 1 major effect of simvastatin
was inhibition of the induction of Smad6 and Smad7,
inhibitory Smads that inhibit TGF-b signaling. The in-
vestigators suggested that 1 mechanism responsible for the
immunosuppressive effects of statins is the ability to pro-
mote the generation of Foxp3þ T regulatory cells (60).
Direct inhibitory effects of statins on T-cell activation and
function, independent of antigen-presenting cells or Tregs,
have been reported over the past years, although the
mechanisms involved are not well characterized. Further-
more, the induction of Kruppel-like factor 2 (KLF2)
may be the key to how statins alter T-cell function. KLF2
regulates the expression of molecules essential for naive
T-cell recirculation and maintenance of T-cell quiescence.
Bu et al. (61) showed that statins blocked activation-
induced down-regulation of KLF2 in naive mouse and
human T cells, and elevated KLF2 expression in effector T
cells in a mevalonate-dependent fashion.In addition, statins blocked proliferation and T-cell IFN-g
expression in a KLF2-dependent manner. In a mouse model
of myocarditis involving adoptive transfer of heart antigen-
speciﬁc T cells, statin treatment of transferred cells had
effects similar to ectopic KLF2 expression in attenu-
ating disease severity. One possible mechanism by which
statins might enhance KLF2 expression is by inhibiting
the mammalian target of rapamycin complex 1 (MTORC1)
activation, a known inhibitor of KLF2 expression in acti-
vated T cells (62). In this regard, it is of interest that Ras
homolog enriched in brain (Rheb), an isoprenylated Ras
family GTPase, is required for MTORC1 activation. A
recent study has revealed that statin inhibition of Rheb
activation blocks MTORC1 activation in VSMCs, leading
to impaired differentiation (63). Statins are known to reduce
T-cell cytotoxicity in various in vitro assays. The number
of CD4þ T cells with TGF-related apoptosis-inducing
ligand (TRAIL)-dependent cytotoxic activity against ECs
and SMCs is increased in patients with ACS, and these cells
are implicated in plaque destabilization. Recent experimental
evidence showed that CD4þ T cells from statin-treated pa-
tients with ACS were less effective in TRAIL-dependent
killing of ECs than T cells from patients not treated with
statins. In in vitro assays, rosuvastatin, ﬂuvastatin, and
pitavastatin directly blocked CD4 T-cell-mediated EC
apoptosis and reduced T cell-expression of CD69 and
TRAIL through TCR-induced ERK activation (64).
Effect of Statins on Circulating
Pro-Inﬂammatory Cytokines
Early-stage atherogenesis entails leukocyte/endothelial in-
teraction and accumulation of inﬂammatory cells; statins
were shown to inhibit adhesion of leukocytes to ECs (65).
Furthermore, HMG-CoA reductase inhibitors regulate
the expression of chemokines controlling the migration of
leukocytes to subendothelial sites of inﬂammation, such
as MCP-1 and IL-8. Simvastatin was shown to reduce
the expression of pro-inﬂammatory cytokines such as
IL-6, IL-8, and MCP-1 in peripheral blood mononuclear
cells from patients with hypercholesterolemia both
in vitro and in vivo (66). MMPs were also described to be
implicated in the process of monocyte/macrophage
migration, and it has been revealed that statins dimin-
ished their expression. Thus, HMG-CoA reductase in-
hibitors lower the expression and function of a broad
range of MMPs, including interstitial collagenases (MMP-1,
MMP-13), gelatinases (MMP-2, MMP-9), and stromelysin
(MMP-3).
Effect of Statins on Adhesion Molecules
Leukocyte transendothelial migration is regulated by the
cooperative actions of ICAM-1 and VCAM-1 on both ECs
and the leukocytes. Leukocytes cross ECs either through
intercellular junctions (paracellular pathway) or through
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2500the EC body (transcellular pathway). Paracellular trans-
endothelial migration involves PECAM-1 and members of
the JAM family (67–69).
The Rho family consists of 22 genes encoding at least 25
proteins in humans, of which the Rho, Rac, and Cdc42
proteins have been studied in the most detail (70,71).
Within the Rho family, there are subgroups of closely related
isoforms including Rho (A, B, C) and Rac (1, 2, 3). All Rho
family members bind GTP, and most exhibit GTPase ac-
tivity, cycling between an inactive GDP-bound form and an
active GTP-bound form. Rho GTPase function is also
regulated by their localization. Rho is required for leukocyte
adhesion to ECs, for clustering of ICAM-1 and VCAM-1,
and for formation of docking structures around adherent
leukocytes (72,73). Most Rho family proteins undergo post-
translational modiﬁcation by prenylation of a cysteine res-
idue located 4 amino acids from the C terminus, followed by
methylation of this cysteine and proteolytic removal of the
last 3 amino acids. The prenyl group helps anchor the
protein to membranes.
Isoprenoids are intermediates in the pathway to choles-
terol synthesis, and their production is reduced by statins. As
mentioned previously, some of the pleiotropic effects of
statins are due to the inhibition of farnesyl-pyrophosphate
and geranylgeranyl-pyrophosphate synthesis, the isopren-
oids required for prenylation of Rho proteins. Statins
thereby modulate Rho family protein subcellular localiza-
tion, and this affects their stability and activity. Statins also
alter Rho expression at the transcriptional level, although the
mechanistic basis for this is not clear (74,75). Indirect evi-
dence suggests that Rho GTPases regulate PECAM-1
expression on the EC surface. Statins not only affect the
total levels of PECAM-1 in different EC lines (76,77)
but also modulate PECAM-1 localization (76). Moreover,
C3 transferase treatment mimics the effect of statins on
PECAM-1 expression (76).
Statin Effects on Coenzyme Q10
Coenzyme Q10 is a lipid molecule composed of a 1,4-
benzoquinone along with 50 carbon atoms and is an
essential component of the inner membrane of mitochon-
dria, acting as an electron transporter during ATP synthesis
(78). The reduced form of coenzyme Q10, ubiquinol, has
been demonstrated to prevent oxidation of key biological
molecules such as proteins, lipids, and DNA. In addition, it
is almost exclusively bound to the lipoprotein transport of
LDL. Many studies have revealed that coenzyme Q10 has
anti-inﬂammatory effects due to its ability to prevent LDL
oxidation (79). Because coenzyme Q10 is synthesized from
the mevalonate pathway, it is evident that statin adminis-
tration inhibits its synthesis, often resulting in some
adverse effects. Often, depletion of coenzyme Q10 can
cause adverse effects, namely, myalgia and fatigue (80).
Several studies conﬁrm the fact that statin administration
reduces serum levels of coenzyme Q10 (81,82). However,there is still a debate about whether this depletion can
actually affect mitochondrial function (83). Other factors
affecting circulating levels of coenzyme Q10 are age and
exercise.
In a substudy of the CORONA (Controlled Rosuvastatin
Multinational Study in Heart Failure) trial, coenzyme Q10
levels were assessed in 1,191 patients and were found lower
in older patients with more severe signs of heart failure.
Reduction in coenzyme Q10 levels was associated with
worse clinical outcome in heart failure, suggesting that co-
enzyme Q10 can be used as a marker of advanced dis-
ease state, but not as an independent prognostic marker.
Furthermore, statin treatment resulted in reduced levels of
coenzyme Q10, although statin therapy has not been asso-
ciated with worse clinical outcome, perhaps due to lack of
statistical power or simply because its clinical signiﬁcance
is balanced by the beneﬁcial effects of statin treatment on
cardiovascular risk in these patients (84).
Conclusions
Given the fact that atherosclerosis is a multivariable disease,
with several molecules involved in each stage, it is very
difﬁcult to ﬁnd an effective treatment. However, statins
prove to be the most effective treatment so far because they
interfere with most of the critical components of the
atherosclerotic process and have been proven to have bene-
ﬁcial effects. Further to their well-established impact on
nonspeciﬁc low-grade inﬂammation, statins also appear to
have signiﬁcant effects on innate and adaptive immunity
that have been underestimated so far. It is certain that their
full potential has not yet been revealed and that they will
remain the agent of choice for combating atherosclerosis
and its related diseases.
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